Biotech company Emergex Vaccines Holding Limited has raised over $11 million in a Series A round led by Singapore-based venture capital firm Vickers Venture Partners, according to a statement.
Founded in 2016, Emergex, a UK-based biotechnology company, claims to have developed vaccines to address some of the world’s most immediate health threats such as Dengue Fever, Zika, Ebola, pandemic flu and serious intra-cellular bacterial infections.
With this investment, Chairman of Vickers Venture Partners Dr. Finian Tan will join Emergex’s board of directors. Vickers will assist Emergex with growth at the strategic level and connect the company to its networks of investment and industry partners.
The financing supports the progress of Emergex’s development pipeline, including a first-in-man Phase 1 clinical trial of its Flavivirus (Dengue) vaccine in Switzerland, as well as Phase 1b clinical trials in the endemic regions of Singapore and Brazil.
Proceeds will also support the Universal Influenza and Filovirus programmes through the preclinical stages and early clinical trials.
Emergex’s technology “allows vaccines to be produced quickly, administered easily and sold at a fraction of current prices,” said Dr Finian Tan, chairman of Vickers Venture Partners.
Vickers Venture Partners is one of the leading venture capital firms focused on life sciences and deep tech.
Recently, Vickers has co-led $40 million in an oversubscribed financing round in Singapore-headquartered medical technology company AWAK Technologies.
In September, we reported that Vickers Venture Partners was set to hit the first close of its $500 million sixth fund in the first week of October. Vickers’s $500-million sixth fund is one of Southeast Asia’s largest VC funds, targeting to invest in 30 to 50 companies in biotechnology, nanotechnology, and artificial intelligence.